Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 14/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323748 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7922849 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7922851 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL4085510 | 0.90 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL8332109 | 0.90 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2584027 | 0.86 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3316264 | 0.85 | P2RY14 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2580691 | 0.84 | P2RY2 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7257091 | 0.83 | TYMP (0.47) | TYMP | |
| SCHEMBL7257093 | 0.83 | TYMP (0.47) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-6214551-B1 | CONTACTING TEST SOLUTION CONTAINING NUCLEIC ACID WITH COMPOUND CONTAINING NUCLEOSIDE SEQUENCE WHEREIN NUCLEOSIDES ARE COVALENTLY BOUND THROUGH LINKING GROUP HAVING ADJACENT NITROGEN ATOMS FOR ASSAYING SEQUENCE-SPECIFIC NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-0586570-B1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6025482-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5965721-A | WITH IMPROVED NUCLEASE RESISTANCE AND IMPROVED CELLULAR UPTAKE; FOR ANTISENSE AGENTS AND REGULATION OF RNA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5610289-A | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0586570-A4 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | RNASE1, RNGTT, NSUN2 | SLC28A1 139/4885SLC28A2 131/4885SLC29A1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.